Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ariana Maia Becerra, MÁrquez"'
Publikováno v:
Maedica (Bucur)
Introduction: Hemophagocytic syndrome (HS) is a potentially fatal hyperinflammatory condition characterized by excessive activation of macrophages and T cells. Systemic lupus erythematosus (SLE) is an autoimmune condition that predisposes to HS. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3eb0c0be5776fe9f7ed6a42f985dbce2
https://pubmed.ncbi.nlm.nih.gov/33603918
https://pubmed.ncbi.nlm.nih.gov/33603918
Publikováno v:
International Journal of Biomedical Engineering and Clinical Science. 7:73
Objetives. To determine the correlation between prolactin levels and disease activity classified based on the Mexican lupus erythematosus disease systemic activity index (MEX SLEDAI).Methods. In this cross-sectional observational study, serum prolact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a8eb9456cd6d6d062e9953c7a7fecd
https://doi.org/10.11648/j.ijbecs.20210704.11
https://doi.org/10.11648/j.ijbecs.20210704.11
Autor:
Laura Elena Aranda Baca, Yadhira Mejía Holguín, Ariana Maia Becerra Márquez, Rosa Elena Calderón Saldierna, María Josefina Sauza del Pozo, María Azucena Ramos Sánchez
Publikováno v:
Reumatología Clínica. 6:82-85
Resumen En algunos casos la trombocitopenia secundaria a lupus eritematoso sistemico (LES) no responde al tratamiento convencional. En los ultimos anos se ha reportado que el rituximab es una alternativa para estos pacientes. Objetivo Evaluar la resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::878765497564cd32abaf309b3fd2c0fb
https://doi.org/10.1016/j.reuma.2009.04.013
https://doi.org/10.1016/j.reuma.2009.04.013
Autor:
Rosa Elena Calderón Saldierna, Laura Elena Aranda Baca, María Josefina Sauza del Pozo, Ariana Maia Becerra Márquez, María Azucena Ramos Sánchez, Yadhira Mejía Holguín
Publikováno v:
Reumatología Clínica (English Edition). 6:82-85
Some patients with thrombocytopenia due SLE fail to respond to conventional therapies. Rituximab has been reported to be an alternative for patient treatment. Objective To evaluate the response of thrombocytopenia due to Systemic Lupus Erythematosus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc708f969a3f1e48a9a505b3e96264c2
https://doi.org/10.1016/s2173-5743(10)70018-6
https://doi.org/10.1016/s2173-5743(10)70018-6